Clinical Trials Logo

Cannabis clinical trials

View clinical trials related to Cannabis.

Filter by:

NCT ID: NCT02710331 Active, not recruiting - Cannabis Clinical Trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

THC-ETOH-III
Start date: March 2016
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

NCT ID: NCT02710097 Active, not recruiting - Cannabis Clinical Trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II

THC-ETOH-II
Start date: March 2016
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

NCT ID: NCT02709954 Active, not recruiting - Cannabis Clinical Trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I

THC-ETOH-I
Start date: March 2016
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

NCT ID: NCT02635568 Completed - Pregnancy Clinical Trials

Duration of Marijuana Concentration in Breast Milk- A Pilot Study

Start date: November 2016
Phase:
Study type: Observational

Legalization of marijuana in Colorado for both medicinal and recreational purposes has led to a perception of its safety, which has not been well studied in pregnant or lactating women. The psychoactive component of marijuana, delta-9-tetrahydrocannabinol (THC) is lipophilic and therefore presumed to be secreted into breast milk. Additionally, the difference between modes of consumption (ie. smoked vs. edible) has not been well described in regards to THC concentration in breast milk. The purpose of this small pilot study is to describe the presence and duration of THC expression in breast milk among women who have evidence of THC exposure at the time of labor and delivery or within 72 hours of delivery. The researchers hypothesize that women with positive urine drug screen for THC within 72 hours of delivery may excrete THC in breast milk for a predicted period of time, and therefore the aim of this project is to determine timing to safely return to breastfeeding to decrease infant exposure to THC. The specific aims are to determine in women who test positive for THC at delivery: 1. Determine length of time THC and metabolites are detected in breast milk of mothers who have a positive urine drug screen at the time of presentation for labor and delivery or within 72 hours of delivery. 2. Determine length of time THC and metabolites are detected in breast milk of mothers with postnatal exposure of either ingested or inhaled marijuana, to inform recommendations on when to safely return to breastfeeding. 3. Describe modes of marijuana consumption in women presenting for delivery and correlate with THC concentrations and persistence in breast milk.

NCT ID: NCT02567344 Completed - Cannabis Clinical Trials

Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving

Start date: October 2015
Phase: N/A
Study type: Interventional

This is a double-blind, crossover trial that will recruit a cohort of non-treatment seeking Cannabis use disordered participants. Participants will then undergo either active, or sham rTMS to the LDLPFC, and cue-induced craving, and risky decision making will be assessed.

NCT ID: NCT02460692 Completed - Low Back Pain Clinical Trials

Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This study will involve treating low back pain associated with nerve injury with oral delta-9-tetrahydrocannabinol (Δ9-THC) or whole plant cannabis for eight weeks. Research subjects will consume either oral Δ9-THC (dronabinol), vaporized 3.7% Δ9-THC/5.6% CBD, or placebo. An analysis will then be determined to assess the risk--benefit ratio of dronabinol and vaporized 3.7% Δ9-THC/5.6% CBD .

NCT ID: NCT02408640 Completed - Cannabis Clinical Trials

Internet-Based Treatment for Individuals With Regular Cannabis Use: A Randomized Controlled Trial

Start date: June 26, 2015
Phase: N/A
Study type: Interventional

The aim of this randomized controlled trial is to investigate the effects of a Swedish Internet-based treatment program for individuals from the general population with a regular cannabis use. The primary hypothesis to be tested is that the use of the Internet-based treatment program will be associated with more cannabis-free days in comparison to only access to information about cannabis use and its harmful effects. The secondary hypotheses to be tested are: 1. That the use of the Internet-based treatment program will be associated with a larger decline in cannabis consumption (frequency and quantity) among individuals with regular cannabis use in comparison to only access to information about Cannabis use and its harmful effects. 2. That the use of the Internet-based treatment program will be associated with a larger decline in alcohol consumption, depression and anxiety and increased sense of coherence in comparison to only access to information about Cannabis use and its harmful effects. 3. That the proportion of individuals who seek professional help or talk to their relatives or friends about reducing or stopping cannabis use will be greater among those who use the Internet-based treatment program than among those who only have access to information about cannabis use and its harmful effects. Recruitment procedure and baseline measures Study participants will be recruited through an advertisement on Cannabishjalpen.se. Interested individuals will answer questions about gender, age, country of birth, educational attainment, employment, marital status, living situation, and cannabis use. The intervention group Individuals randomized to the intervention group will directly after randomization answer questions about alcohol use, use of drugs other than alcohol and cannabis, depression, anxiety, a sense of context and whether they during the last 12 months has received professional help to reduce or quit their cannabis use or during the same period have raised this issue with their relatives or friends. Further, they will fill out a survey on Internet-based services for individuals who wish to reduce or quit their cannabis use. The study participants will then be informed that they, within two days, will gain access to an internet based treatment program designed to help them quit their cannabis use and that they through the program will have the opportunity to communicate with a therapist. Within the next two days, they will gain access to the internet-based treatment program, they will have access to it for two months and they will be contacted again after three months to answer questions about their cannabis and alcohol use, as well as about other previously mentioned issues. The control group Individuals randomized to the control group will undergo exactly the same procedure as the intervention group. The difference is that the control group will be informed that they in about three months will gain access to an internet based treatment program designed to help them quit their cannabis use (i.e. when the data collection for follow-up is completed). Otherwise, participants in both groups will have the opportunity to use factual information that is available to everyone on Cannabishjalpen.se. Follow-up procedure Study participants who were randomized to the intervention group will have access to intervention in two months. Three months after recruitment to the study, study participants from both groups will get an automated email invitation to participate in the three-month follow-up. The email will include a personalized link that when clicked on will redirect the participant to follow-up page where they will be asked to once again answer questions about their cannabis and alcohol use, depression and anxiety, seeking professional help for cannabis use as well as the help of family or friends and questions about whether they have used any other internet or telephone services to reduce or quit their cannabis use. The entire follow-up procedure will be completed via the internet.

NCT ID: NCT02407808 Active, not recruiting - Psychotic Disorders Clinical Trials

Cannabinoids, Learning, and Memory

THC-Memory
Start date: February 2015
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.

NCT ID: NCT02404688 Active, not recruiting - Cannabis Clinical Trials

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

THC-ETOH
Start date: December 2015
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

NCT ID: NCT02165176 Completed - Cannabis Clinical Trials

Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis

Start date: June 2014
Phase: Phase 1
Study type: Interventional

Few studies have been conducted to assess the pharmacokinetic and pharmacodynamic effects of orally consumed intact cannabis (e.g., cannabis-containing brownies). Careful analysis of oral cannabis dose effects on these parameters is required to determine the level and duration of biological cannabinoid exposure and associated subjective, cardiovascular and cognitive effects. In the present study we evaluated the detection of cannabinoids in oral fluid, plasma, hair, and urine for up to 9 days following consumption of oral cannabis (10mg, 25mg, or 50mg THC). The outcomes of the study will extend scientific knowledge about the behavioral pharmacology and toxicology of oral cannabis administration and can inform policies regarding clinical, workplace and roadside drug testing programs.